Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 4 - The Real Truth

What Are Wall Street Analysts' Target Price for Amgen Stock?

Amgen has outperformed the broader market and many of its peers over the past year, but Wall Street analysts believe it has limited upside left.

Barchart

3 Biotech Stocks Poised for May Surges

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.

StockNews.com

AMGN Earnings Spotlight: Analyzing Potential Gains

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Analyzing 3 Biotech Stocks for 2024 Gain Potential

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

StockNews.com

3 Biotech Stocks Signaling Buy Opportunities

The biotech industry is well-positioned to generate returns amid breakthrough developments and the growing prevalence of chronic diseases. Given the solid long-term prospects of the industry, fundamentally sound biotech stocks Entrada Therapeutics (TRDA), Alkermes (ALKS) and Amgen (AMGN) could be ideal buys for steady gains. Read on.

StockNews.com

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

StockNews.com

Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

StockNews.com

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

3 Best Biotech Stocks for Health and Wealth

With medical innovations and technological breakthroughs rapidly transforming the healthcare landscape, biotech stocks have garnered unprecedented attention in the investment community. Thus, fundamentally robust stocks like Incyte Corp. (INCY), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) could contribute to the health and wealth of your portfolios. Read more….

StockNews.com

The Top 3 Dividend Stocks to Buy Today

Amid persistently high inflation, rising interest rates, and other macroeconomic headwinds, the stock market is expected to remain highly uncertain in the upcoming months. Therefore, it could be wise to invest in dividend-paying stocks Amgen (AMGN), Kimberly-Clark (KMB), and OneMain Holdings (OMF) to ensure a steady income stream. Keep reading….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals (REGN), United Therapeutics (UTHR), and Vanda Pharmaceuticals (VNDA) with “Strong Buy” ratings could be wise portfolio additions now. Read on….

StockNews.com

2 Healthcare Stocks Showing Stability With A and B POWR Ratings

The healthcare industry should thrive with accelerated breakthrough developments and a growing market for telemedicine and personalized medicines. Moreover, given the lingering macroeconomic headwinds, fundamentally strong healthcare stocks, Amgen (AMGN), and Otsuka Holdings (OTSKY) showing Stability with A and B POWR Ratings could be ideal buys. Read more.

StockNews.com

3 High-Quality Stocks to Add to Your Watchlist Now

Despite the bank failures, the Fed will likely keep raising interest rates to bring inflation down. This is expected to keep the stock market under pressure. Amid this backdrop, it could be wise for investors to add high-quality stocks Visa (V), Amgen (AMGN), and Box (BOX) to their watchlist. Keep…

StockNews.com

2 Top Biotech Stocks to Buy in March

The biotech industry is expected to witness solid growth amid impressive advancements and government initiatives. Moreover, the biotech sector tends to be more defensive than others during market downturns. So, fundamentally sound biotech stocks Amgen (AMGN) and Biogen (BIIB) might be ideal buys now. Keep reading.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Dow Stocks to Buy More of in March 2023

With the Fed keen on further interest rate hikes this year, the stock market will likely remain under pressure. Amid this backdrop, it could be wise for investors to buy fundamentally strong Dow stocks like Verizon Communications (VZ), Amgen (AMGN), and International Business Machines (IBM). Read more….

StockNews.com

4 Stocks to Buy in Any Market Climate

The stock market is expected to remain volatile in the near term as investors remain anxious about the Fed’s actions. Amid high recession worries, fundamentally strong healthcare stocks, Pfizer (PFE), Bristol-Myers Squibb (BMY), Amgen (AMGN), and Elevance Health (ELV), which have the potential to withstand any market downturns, could be…

StockNews.com

3 Biotech Stocks With Potential to Be Big Winners in 2023

The biotech industry is well-positioned to grow strongly, given the ever-rising demand for therapies and favorable government initiatives. Looking at the industry’s long-term prospects, fundamentally strong biotech stocks Amgen (AMGN), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) could emerge as big winners this year. Keep reading….

StockNews.com

3 Biotech Stocks to Buy and Hold for the Next 20 Years

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

StockNews.com

3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

StockNews.com

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

StockNews.com

4 Biotech Stocks to Keep an Eye on in 2023

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could…

1 … 3 4 5 6

People

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.